AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

November 15, 2020

Video

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!

Recent Videos

Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting

At EURETINA 2025, Stela Vujosevic, MD, PhD, FEBO asks, "as part of the symposium on diabetes and vascular disease, "Do we need a new staging for diabetic retinopathy and macular edema?"

At EURETINA, Professor Harvey Uy described the ways artificial intelligence can augment an existing imaging workflow.

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Newsletter